Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Tiotropium high dose Clear all
Completed Phase 3 Interventional Results available

A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD

NCT01525615
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Respimat inhaler, tiotropium+olodaterol (low dose), tiotropium + olodaterol (high dose), placebo to tiotropium+olodaterol
Device · Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 75 Years
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
15
States / cities
Torrance, California • Hartford, Connecticut • Springfield, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2016 · Synced Sep 17, 2026, 5:46 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma

NCT01634139
View directory record Official record
Conditions
Asthma
Interventions
Tiotropium low dose QD, Tiotropium high dose QD, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
6 Years to 11 Years
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
6
States / cities
Columbia, Missouri • Cincinnati, Ohio • Oklahoma City, Oklahoma + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Sep 17, 2026, 5:46 PM EDT
Completed Phase 3 Interventional Results available

To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways

NCT02085161
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
placebo to tiotropium + olodaterol, tiotropium +olodaterol, tiotropium
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 75 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
San Diego, California • Torrance, California • Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 5, 2017 · Synced Sep 17, 2026, 5:46 PM EDT
Completed Phase 3 Interventional Results available

Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)

NCT01431287
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium + olodaterol, tiotropium, olodaterol, Respimat
Drug · Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
2,539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
38
States / cities
Greer, California • Fort Collins, Colorado • Danbury, Connecticut + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2015 · Synced Sep 17, 2026, 5:46 PM EDT
Completed Phase 3 Interventional Results available

Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.

NCT01533935
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Placebo, tiotropium + Olodaterol, Tiotropium, Olodaterol, Respimat
Drug · Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 75 Years
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
11
States / cities
Phoenix, Arizona • Austell, Georgia • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2015 · Synced Sep 17, 2026, 5:46 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I

NCT01172808
View directory record Official record
Conditions
Asthma
Interventions
Placebo, tiotropium Respimat® low dose, tiotropium Respimat® high dose, 50 mcg salmeterol HFA MDI
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,071 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
21
States / cities
Huntington Beach, California • Mission Viejo, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2014 · Synced Sep 17, 2026, 5:46 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma

NCT01634113
View directory record Official record
Conditions
Asthma
Interventions
tiotropium-bromide, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
1 Year to 5 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
4
States / cities
Columbia, Missouri • Oklahoma City, Oklahoma • Charleston, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2015 · Synced Sep 17, 2026, 5:46 PM EDT
Completed No phase listed Observational Results available

Impact of Tiotropium Add-on Therapy in Patients With Asthma

NCT03964220
View directory record Official record
Conditions
Asthma
Interventions
Tiotropium Respimat®, Inhaled Corticosteroid/Long-acting beta-agonist
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years and older
Enrollment
7,857 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
White Plains, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Sep 17, 2026, 5:46 PM EDT
Completed Phase 3 Interventional Results available

Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.

NCT02296138
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
olodaterol, tiotropium
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
7,903 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
117
States / cities
Andalusia, Alabama • Birmingham, Alabama • Florence, Alabama + 100 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2018 · Synced Sep 17, 2026, 5:46 PM EDT
Completed Phase 3 Interventional Results available

Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients

NCT01533922
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Placebo, Tiotropium, Olodaterol, Tiotropium + Olodaterol, Respimat
Drug · Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 75 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
8
States / cities
Torrance, California • Hartford, Connecticut • Livonia, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2015 · Synced Sep 17, 2026, 5:46 PM EDT
Completed Phase 3 Interventional Results available

Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)

NCT02006732
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
olodaterol, tiotropium, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
809 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
20
States / cities
Jasper, Alabama • Stamford, Connecticut • Clearwater, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2016 · Synced Sep 17, 2026, 5:46 PM EDT
Completed Phase 2 Interventional Results available

Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)

NCT00696020
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
BI 1744 CL/tiotropium bromide fixed dose combination, tiotropium bromide, Respimat® Inhaler
Drug · Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
22
States / cities
Riverside, California • San Diego, California • Wheat Ridge, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2015 · Synced Sep 17, 2026, 5:46 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent Asthma

NCT01634152
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Tiotropium low dose mcg, Tiotropium high dose
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
6 Years to 11 Years
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
10
States / cities
Rolling Hills Estates, California • Denver, Colorado • North Dartmouth, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Sep 17, 2026, 5:46 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of 2 Doses of Tiotropium Respimat Compared to Placebo in Adolescents With Severe Persistent Asthma

NCT01277523
View directory record Official record
Conditions
Asthma
Interventions
tiotropium high dose, placebo, tiotropium low dose
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years to 17 Years
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
8
States / cities
Stockton, California • Normal, Illinois • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2014 · Synced Sep 17, 2026, 5:46 PM EDT
Completed Phase 3 Interventional Results available

Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease

NCT01559116
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium + olodaterol, tiotropium, olodaterol, Placebo, Respimat
Drug · Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
Jasper, Alabama • Easley, South Carolina • Greenville, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2015 · Synced Sep 17, 2026, 5:46 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II

NCT01172821
View directory record Official record
Conditions
Asthma
Interventions
placebo, tiotropium Respimat® low dose, tiotropium Respimat® high dose, 50 mcg salmeterol HFA MDI
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,032 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
18
States / cities
Los Angeles, California • Stockton, California • Centennial, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2014 · Synced Sep 17, 2026, 5:46 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma

NCT01257230
View directory record Official record
Conditions
Asthma
Interventions
tiotropium Respimat low dose, placebo Respimat, tiotropium Respimat high dose
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years to 17 Years
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Plymouth, Minnesota • Columbia, Missouri • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2014 · Synced Sep 17, 2026, 5:46 PM EDT
Completed Phase 3 Interventional Results available

Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)

NCT01964352
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium, placebo, olodaterol
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
20
States / cities
Wheat Ridge, Colorado • Clearwater, Florida • Panama City, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2015 · Synced Sep 17, 2026, 5:46 PM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease

NCT01040728
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Olodaterol (BI1744) Low, Olodaterol (BI1744) High, Tiotropium 18 mcg, Placebo (for Olodaterol (BI1744)l), Placebo (for Tiotropium)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
3
States / cities
Jasper, Alabama • Clearwater, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 29, 2014 · Synced Sep 17, 2026, 5:46 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Multiple Doses of QAX028 in Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT01068613
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
QAX028, Tiotropium, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
4
States / cities
Anaheim, California • Normal, Illinois • Spartanburg, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 17, 2026, 5:46 PM EDT
Completed Phase 2 Interventional

High Dose Trial in COPD

NCT00128440
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
BEA 2180 BR, tiotropium
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 84 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
13
States / cities
Lakewood, California • Wheat Ridge, Colorado • Pembroke Farms, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2013 · Synced Sep 17, 2026, 5:46 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis

NCT00737100
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Placebo Respimat, Tiotropium bromide 5 mcg, tiotropium bromide-low dose-2.5mcg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
Not listed
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
26
States / cities
Tucson, Arizona • San Diego, California • Jacksonville, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced Sep 17, 2026, 5:46 PM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.

NCT00528996
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
BEA 2180 BR, Tiotropium Bromide, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 100 Years
Enrollment
2,080 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
56
States / cities
Jasper, Alabama • Mobile, Alabama • Berkeley, California + 50 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Sep 17, 2026, 5:46 PM EDT
Completed Phase 3 Interventional Results available

Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)

NCT01431274
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium + olodaterol, tiotropium, olodaterol, Respimat
Drug · Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
2,624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
35
States / cities
Jasper, Alabama • Mobile, Alabama • Boulder, Colorado + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2015 · Synced Sep 17, 2026, 5:46 PM EDT